Bivalirudin

Bivalirudin is a reversible direct thrombin inhibitor used for anticoagulation during PCI.

gmgmcg
mlL
kglbs
mg/kg/minmg/kg/hrmcg/kg/minmcg/kg/hr

使用適応

Used to support PCI in STEMI (reduces mortality/major bleeding vs UFH) and may be used in NSTE‑ACS PCI mainly to reduce bleeding 1 [Level I evidence]. Also indicated for patients with heparin‑induced thrombocytopenia undergoing PCI 2 [Level I evidence]. Clinical utility: lowers major bleeding (e.g., 3.3% vs 5.5% with UFH in NSTEMI PCI 3 [Level I evidence]) with similar ischemic outcomes.

洞察と注意事項

Reduces bleeding vs heparin, especially in femoral PCI, but may increase acute stent thrombosis without a full 2–4 h post‑PCI infusion 1 [Level I evidence].
Use lower infusion (1 mg/kg/h) if CrCl <30 mL/min 1 [Level I evidence].
Preferred in HIT 2 [Level I evidence].
Bleeding advantage diminishes with radial access 3 [Level II evidence].